human
eukaryot
cell
highmannosetyp
glycan
hmg
appear
earlystag
nglycosyl
nascent
polypeptid
within
endoplasm
reticulum
immatur
oligosaccharid
subsequ
process
hybrid
complex
glycoform
protein
secret
golgi
apparatu
reach
cell
membran
henc
hmg
rare
found
extracellular
environ
normal
condit
howev
wide
known
envelop
env
glycoprotein
hiv
heavili
glycosyl
hmg
glycan
gener
serv
shield
protect
neutralizationsensit
conserv
env
region
humor
immun
attack
recent
studi
reveal
fraction
broadli
neutral
antibodi
bnab
evolv
target
hmg
shield
hivinfect
individu
provid
implic
hiv
vaccin
develop
carbohydratebind
protein
lectin
wide
found
anim
plant
microorgan
play
critic
role
divers
biolog
process
includ
cellular
signal
microbehost
interact
host
defens
lectin
util
mani
biolog
applic
includ
cell
profil
lectin
microarray
affin
chromatographi
use
immobil
lectin
histochemistri
cytochemistri
medic
diagnosi
biosensor
environment
monitor
addit
sever
lectin
divers
origin
shown
immunomodulatori
antitumor
antimicrobi
antivir
effect
highlight
potenti
use
drug
notwithstand
therapeut
potenti
demonstr
vitro
develop
lectinbas
antivir
therapeut
remain
underdevelop
area
due
toxic
andor
limit
avail
actinohivin
ah
actinomycetederiv
lectin
recogn
termin
mannos
residu
hmg
ah
shown
neutral
hiv
without
induc
cytotox
mitogen
human
blood
cell
suggest
lectin
may
provid
use
tool
develop
new
hmgtarget
agent
major
drawback
howev
ah
highli
hydrophob
prone
aggreg
thu
recalcitr
effici
recombin
product
hamper
develop
drug
andor
biolog
tool
engin
new
ah
variant
improv
biochem
pharmaceut
properti
use
plantvirusvectorbas
transient
overexpress
system
rapid
screen
scalabl
product
platform
solubl
variant
term
avaren
actinohivin
variant
express
nicotiana
obtain
structureguid
mutat
subsequ
fuse
fragment
crystalliz
region
fc
human
immunoglobulin
subclass
creat
lectibodi
avfc
data
show
avfc
highli
produc
scalabl
plantbas
system
antihiv
activ
deriv
fc
function
lack
signific
toxic
highlight
potenti
util
novel
hmgtarget
antihiv
strategi
ah
compos
three
nearhomolog
tandem
repeat
domain
harbor
bind
pocket
hmg
hypothes
high
aggreg
propens
ah
could
improv
neutral
surfac
charg
variat
thu
design
multipl
ah
variant
chang
amino
acid
one
two
domain
correspond
residu
domain
three
domain
alik
similar
overal
surfac
charg
properti
exampl
domain
domain
mutat
glu
correspond
domain
figur
screen
variant
use
plantvirusvectorbas
transient
overexpress
system
magnicon
n
benthamiana
five
day
postvector
inocul
dpi
sever
variant
show
higher
level
accumul
leaf
tissu
ah
figur
variant
readili
extract
leaf
tissu
pb
indic
improv
solubl
direct
elisa
hiv
env
glycoprotein
elisa
show
variant
accumul
highest
level
reach
mg
kg
leaf
tissu
retain
capac
figur
well
antihiv
activ
figur
contrast
ah
recov
leaf
tissu
pb
extract
mg
kg
leaf
tissu
data
shown
variant
name
avaren
total
amino
acid
ah
modifi
creat
avaren
figur
addit
disulfid
bond
introduc
rim
sugarbind
pocket
domain
origin
found
domain
confirm
peptid
map
figur
circular
dichroism
cd
analysi
reveal
increas
random
coil
avaren
structur
figur
top
panel
nevertheless
overal
structur
appear
similar
ah
figur
bottom
panel
homolog
model
show
close
superimpos
structur
ah
avaren
albeit
loss
b
strand
hing
domain
avaren
figur
melt
temperatur
avaren
ah
determin
cd
c
indic
similar
structur
stabil
collect
conclud
avaren
better
recombin
produc
plant
ah
retain
overal
conform
function
properti
avaren
translat
fuse
fc
region
human
antibodi
avfc
anticip
antibodylik
molecul
lectibodi
may
possess
sever
advantag
parent
lectin
includ
higher
hmgbind
avid
via
dimer
prolong
vivo
halflif
fcmediat
antiviralantitumor
function
antibodydepend
cellmedi
cytotox
adcc
upon
express
n
benthamiana
use
plant
viru
vector
avfc
accumul
signific
portion
total
solubl
leaf
protein
day
effici
purifi
homogen
figur
approxim
g
purifi
avfc
obtain
kg
plant
biomass
pilotscal
product
facil
determin
avfc
sugar
bind
specif
glycan
array
analysi
perform
among
mammalian
glycan
analyz
ah
avfc
show
high
specif
oligomannos
glycan
contain
termin
mannos
figur
elisa
lectibodi
sugarbind
abil
abrog
upon
treatment
mannosidas
unlik
bindingsitespecif
bnab
similarli
envglycanspecif
bnab
figur
result
demonstr
avfc
retain
high
hmg
specif
origin
lectin
ah
notwithstand
surfac
plasmon
reson
spr
analysi
reveal
lectibodi
increas
affin
recombin
hiv
protein
approxim
compar
ah
figur
figur
investig
whether
increas
affin
avfc
translat
enhanc
antivir
effect
first
perform
viru
captur
assay
use
envpseudotyp
virus
shown
figur
avfc
caught
virion
effect
ah
three
strain
test
pseudoviru
neutral
assay
use
clone
avfc
show
significantli
potent
activ
ah
inhibitori
concentr
ic
nm
versu
nm
ah
similar
figur
result
demonstr
avfc
significantli
potent
neutral
activ
ah
addit
lectibodi
show
significantli
stronger
neutral
effect
viru
produc
gnti
cell
line
thu
display
higher
amount
env
hmg
viru
produc
standard
cell
line
sharp
contrast
bnab
whose
neutral
activ
appear
indiffer
env
hmg
level
figur
thu
result
indic
neutral
activ
avfc
proport
total
amount
hmg
present
viral
surfac
confirm
avfc
antihiv
activ
test
inhibitori
activ
differ
primari
hiv
strain
produc
human
peripher
blood
mononuclear
cell
pbmc
furthermor
use
human
pbmc
four
differ
donor
target
cell
instead
cell
line
use
pseudoviru
assay
lectibodi
exhibit
significantli
stronger
inhibitori
activ
ah
p
wilcoxon
matchedpair
test
group
virus
also
group
strain
median
ic
nm
mgml
avfc
versu
nm
mgml
ah
figur
b
sdspage
perform
analyz
crude
extract
n
benthamiana
leav
express
ah
variant
stain
coomassi
brilliant
blue
dpi
leaf
protein
extract
pb
ph
contain
mm
ascorb
acid
use
buffertoleaf
ratio
ni
noninfiltr
leaf
extract
ev
emptyvectorinfiltr
leaf
extract
ah
ahexpress
leaf
extract
lane
leaf
extract
ah
variant
c
quantif
ah
variant
n
benthamiana
leaf
tissu
use
direct
elisa
total
protein
hatch
bar
protein
black
bar
detect
rabbit
antiah
antiserum
variant
design
avaren
cd
analysi
faruv
cd
top
nearuv
cd
bottom
spectra
ah
avaren
e
crystal
structur
ah
pdb
orang
superimpos
homolog
model
avaren
green
shown
top
side
view
pymol
softwar
homolog
model
perform
swissmodel
use
ah
templat
zoom
imag
surfaceexpos
loop
domain
amino
acid
box
tabl
avfc
capabl
bind
aforement
fcgr
confirm
flow
cytometri
use
fcgriand
fcgriiiaexpress
cell
figur
contrast
avfc
gln
mutat
elimin
nglycosyl
fc
region
correspond
human
igg
therebi
significantli
reduc
affin
fcgr
show
dramat
reduc
bind
receptor
figur
tabl
data
suggest
fc
region
avfc
may
capabl
exhibit
function
properti
fcmediat
biolog
activ
avfc
bind
fcgri
fcgriiia
next
investig
whether
avfc
antihiv
activ
could
also
mediat
fc
function
inde
human
pbmc
infect
assay
show
significantli
reduc
antihiv
activ
compar
figur
design
product
hmgbind
profil
avfc
express
purif
avfc
reduc
sdspage
nonreduc
sdspage
perform
analyz
crude
leaf
extract
purifi
avfc
stain
coomassi
brilliant
blue
repres
gel
imag
shown
left
noninfiltr
leaf
extract
emptyvectorinfiltr
leaf
extract
avfcexpress
leaf
extract
asterisk
indic
avfc
right
purifi
avfc
nonreduc
reduc
condit
nr
nonreduc
condit
r
reduc
condit
b
glycan
array
analysi
sugarbind
profil
ah
top
avfc
bottom
analyz
mammalian
glycan
array
glycan
consortium
function
glycom
glycan
mean
rel
fluoresc
unit
exceed
rank
indic
schemat
diagram
green
circl
indic
mannos
blue
squar
indic
nacetylglucosamin
see
data
avail
complet
dataset
c
analysi
avfc
bind
treat
amannosidas
elisa
perform
avfc
bindingsitespecif
monoclon
antibodi
envelop
hmgbind
monoclon
antibodi
use
recombin
treat
mannosidas
activ
avfc
abolish
treat
env
protein
amannosidas
demonstr
avfc
specif
termin
mannos
residu
hmg
spr
analysi
bind
affin
ah
avfc
bind
kinet
affin
ah
left
avfc
right
measur
use
biacor
instrument
ambient
temperatur
repres
sensorgram
shown
recombin
captur
sensor
chip
surfac
densiti
ru
serial
dilut
avfc
mgml
mgml
ah
mgml
mgml
inject
flow
rate
mlmin
k
determin
base
steadi
state
inset
data
indic
mean
sem
two
independ
analys
avfc
figur
like
reflect
mutant
significantli
lower
bind
affin
fcgr
henc
lack
fcmediat
antivir
effect
furthermor
avfc
show
dosedepend
inhibitori
effect
antibodydepend
cellmedi
viru
inhibit
adcvi
assay
use
primari
human
natur
killer
nk
cell
figur
avfc
adcvi
activ
promin
concentr
mgml
much
stronger
margin
effect
concentr
rang
shown
previou
report
collect
data
indic
addit
virion
neutral
activ
avfc
elicit
fcmediat
antihiv
activ
via
bind
hmg
virus
infect
cell
figur
given
avfc
may
develop
novel
antihiv
agent
next
assess
safeti
vitro
preclin
anim
model
lectibodi
show
signific
bind
beyond
observ
figur
cytotox
figur
mgml
human
pbmc
correspond
time
median
hiv
neutral
ic
figur
sharp
contrast
concanavalin
cona
wellknown
mannosebind
lectin
induc
signific
cytotox
mgml
similarli
flow
cytometri
analysi
avfc
show
induct
activ
marker
hladr
cell
figur
size
morpholog
chang
pbmc
popul
figur
clearli
observ
cona
cytokin
chemokin
releas
profil
pmbc
stimul
avfc
analyz
use
multiplex
bead
array
elisa
qpcr
show
margin
impact
figur
tabl
result
suggest
avfc
littl
mitogen
immunostimulatori
activ
could
pose
increas
risk
hiv
treatment
next
rat
intraven
administ
mg
kg
avfc
avaren
avfc
detect
blood
circul
day
postadministr
wherea
avaren
clear
within
h
figur
extend
halflif
avfc
like
attribut
neonat
fc
receptor
affin
tabl
figur
despit
persist
vivo
avfc
appear
induc
advers
effect
probe
potenti
toxic
lectibodi
administ
mg
kg
twice
week
week
dose
total
mice
chang
observ
behavior
bodi
weight
mice
experi
figur
increas
liver
spleen
weight
observ
day
highdos
avfc
treatment
group
treat
twice
week
p
respect
figur
like
due
immun
reaction
avfc
distinct
patholog
observ
tissu
figur
avaren
human
fc
compon
xenogen
mice
serum
chemistri
show
decreas
blood
urea
nitrogen
calcium
level
dose
avfc
p
respect
figur
tabl
howev
valu
still
within
close
normal
physiolog
rang
addit
although
statist
signific
trend
decreas
note
creatinin
total
bilirubin
level
avfcdos
group
signific
differ
complet
blood
count
paramet
test
avfctreat
vehicl
controltr
mice
figur
tabl
togeth
result
show
overal
lack
major
toxic
upon
avfc
system
administr
aforement
result
justifi
test
avfc
therapeut
potenti
nonhuman
primat
model
hiv
infect
toward
end
first
test
avfc
capac
neutral
three
simian
immunodefici
viru
siv
strain
includ
propag
cell
lectibodi
effect
neutral
virus
ic
valu
nm
respect
figur
addit
avfc
abil
recogn
infect
cell
examin
flow
cytometri
use
rhesu
macaqu
mesenter
lymph
node
mln
cell
infect
vitro
result
show
avfc
mgml
could
dosedepend
recogn
rhesu
mln
cell
notabl
higher
concentr
avfc
show
bind
uninfect
mln
cell
indic
lectibodi
high
select
infect
cell
figur
lastli
two
adult
femal
rhesu
macaqu
subcutan
administ
singl
bolu
dose
mg
mgkg
respect
lectibodi
well
toler
exhibit
averag
halflif
h
figur
flow
cytometri
analysi
macaqu
pbmc
isol
h
avfc
administr
show
evid
select
tempor
redistribut
wwwmoleculartherapyorg
cell
subset
includ
monocyt
dendrit
cell
nk
cell
evid
cell
activ
figur
consist
data
shown
figur
human
pbmc
well
known
hmg
accumul
surfac
hiv
nevertheless
current
drug
target
glycobiomark
report
develop
lectibodi
avfc
recombin
hmgspecif
lectinfc
fusion
protein
avfc
creat
combin
approach
use
structureguid
modif
scalabl
plantvirusvectorbas
transient
overexpress
system
lectibodi
inhibit
wide
rang
hiv
strain
elicit
fcmediat
cytotox
hivinfect
human
pmbc
induc
detect
cell
prolifer
caus
notic
toxic
upon
system
dose
effect
concentr
anim
present
studi
illustr
plant
viral
express
system
provid
power
tool
rapid
screen
effici
product
novel
recombin
protein
quantiti
protein
obtain
eas
multipl
mutant
made
test
use
transient
plant
express
system
demonstr
robust
flexibl
product
platform
greatli
facilit
drug
discoveri
product
initi
effort
focus
engin
ah
mutant
improv
solubl
despit
mutat
mani
ah
amino
acid
avaren
shown
retain
overal
structur
integr
hmgbind
activ
figur
thu
approach
modifi
ah
surfac
charg
properti
met
success
use
expasi
protparam
tool
determin
avaren
theoret
isoelectr
point
pi
grand
averag
hydropath
gravi
valu
wherea
ah
theoret
pi
gravi
valu
accordingli
avaren
overal
lower
surfac
charg
hydrophob
ah
raghunathan
et
al
previous
shown
protein
surfac
charg
engin
modul
protein
stabil
aggreg
properti
thu
find
suggest
improv
manufactur
recombin
protein
critic
mutat
respons
avaren
high
product
yield
appear
modif
surfaceexpos
loop
domain
ctermin
amino
acid
mimic
hydrophil
correspond
residu
domain
addit
charg
surfaceexpos
residu
locat
posit
modul
ie
ah
appear
critic
factor
determin
bioproduc
glu
seem
favor
gln
see
variant
furthermor
avaren
two
new
disulfid
bond
rim
sugarbind
pocket
domain
origin
found
domain
new
disulfid
bond
appear
partli
contribut
high
accumul
level
avaren
leaf
tissu
compar
variant
cysteinefre
variant
variant
show
poor
level
tissu
accumul
similar
ah
figur
possibl
disulfid
bond
collect
facilit
proper
tertiari
structur
format
planta
lead
high
yield
interestingli
variant
accumul
rel
well
leaf
tissu
yet
lost
larg
part
abil
figur
variant
similar
avaren
addit
mutat
includ
asp
ala
ser
asp
ala
ser
combin
result
variant
postul
may
play
role
bind
observ
support
previous
propos
notion
open
space
sugarbind
pocket
asnasp
residu
help
interact
hmg
notabl
avaren
dimer
via
fc
fusion
virtual
impact
sugarbind
profil
origin
molecul
ah
highlight
success
molecular
engin
present
studi
data
indic
avfc
higher
capac
captur
hiv
virion
ah
also
reflect
lectibodi
increas
function
affin
spr
analysi
figur
high
avid
critic
factor
lectin
antivir
activ
exampl
dimer
lectin
griffithsin
significantli
lost
antihiv
activ
protein
mutat
monomer
form
similarli
monom
form
cyanovirinn
contain
two
sugarbind
site
show
reduc
antihiv
activ
one
sugar
bind
site
mutat
restor
activ
upon
dimer
thu
enhanc
antivir
activ
avfc
ah
partli
explain
increas
avid
env
glycan
howev
find
human
primari
cellbas
assay
figur
suggest
signific
part
avfc
antihiv
activ
may
brought
fc
function
particular
strong
adcvi
activ
figur
indic
avfc
effect
recogn
aid
kill
hivinfect
cell
notion
support
find
avfc
show
cytotox
sugarspecif
interact
normal
human
pbmc
figur
effici
bound
uninfect
macaqu
mln
cell
figur
result
highlight
avfc
capac
select
target
hivinfect
cell
unpreced
featur
envglycantarget
lectin
describ
date
result
point
possibl
avfc
could
use
detect
andor
elimin
site
residu
viral
replic
vivo
addit
neutral
free
virus
circul
analyz
potenti
correl
predict
number
env
nglycan
avfc
ic
strain
test
figur
trend
invers
correl
ie
lower
ic
increas
number
glycan
statist
signific
p
pearson
correl
coeffici
figur
slope
avfc
inhibitori
curv
appear
lower
strain
figur
may
due
differ
env
glycosyl
pattern
indic
distinct
antivir
mechan
addit
among
three
siv
strain
test
figur
avfcresist
strain
least
number
predict
env
nglycan
compar
respect
netnglyc
server
tool
specul
glycan
specif
locat
env
rather
total
number
glycan
critic
avfc
neutral
effect
identif
glycan
current
underway
evid
suggest
hiv
evolv
obtain
resist
antivir
lectin
via
deglycosyla
tion
howev
deglycosyl
env
glycoprotein
may
result
unmask
critic
epitop
make
viru
sensit
host
immunoglobulin
avfc
may
still
abl
recogn
kill
infect
cell
express
partial
deglycosyl
env
sinc
complet
deglycosyl
env
unlik
due
critic
role
least
nglycan
env
assembl
viral
infect
addit
abil
avfc
neutral
group
virus
also
group
siv
strain
may
advantag
complement
contemporari
bnab
may
recogn
neutral
beyond
group
virus
hmg
wide
found
glycoprotein
envelop
virus
possibl
avfc
exhibit
neutral
activ
virus
well
preliminari
studi
found
avfc
hold
nanomolar
affin
glycoprotein
hepat
c
viru
variou
influenza
strain
sever
acut
respiratori
syndrom
coronaviru
middl
east
respiratori
syndrom
coronaviru
figur
tabl
although
glycoprotein
show
lower
affin
result
suggest
avfc
could
use
broadspectrum
wwwmoleculartherapyorg
antivir
agent
although
bind
envelop
glycoprotein
alon
guarante
antivir
activ
studi
current
underway
address
possibl
least
two
major
aspect
may
need
address
use
avfc
antivir
therapeut
agent
first
potenti
immunogen
molecul
could
curtail
efficaci
andor
safeti
repeat
treatment
present
anim
studi
suit
address
potenti
immunogen
avfc
fc
domain
avfc
human
origin
would
immunogen
mice
monkey
given
experiment
anim
model
limit
predict
valu
assess
therapeut
protein
immunogen
human
use
avfc
variant
speciesspecif
fc
domain
least
essenti
address
immunogen
question
preclin
studi
inde
issu
sever
potenti
remedi
may
test
minim
immunogen
includ
cell
epitop
delet
pegyl
other
though
studi
beyond
scope
present
report
second
avfc
show
rel
short
serum
halflif
h
rhesu
macaqu
figur
may
part
due
slightli
decreas
affin
fcrn
compar
human
isotyp
control
shown
tabl
potenti
solut
may
modif
fc
region
improv
fcrn
affin
describ
zalevski
et
al
addit
studi
underway
determin
biodistribut
profil
offtarget
bind
potenti
avfc
normal
cell
typic
display
high
amount
hmg
surfac
immatur
glycan
found
enrich
plasma
membran
cancer
cell
embryon
stem
cell
futur
studi
care
evalu
cell
type
hivor
sivinfect
cell
recogn
avfc
conclus
avfc
novel
biolog
candid
target
hivassoci
hmg
abil
avfc
inhibit
divers
hiv
strain
recogn
hivand
sivinfect
primari
cell
coupl
appar
lack
toxic
upon
system
administr
warrant
addit
explor
therapeut
potenti
nonhuman
primat
model
hiv
infect
addit
engin
improv
pharmacolog
profil
deimmun
fc
modif
extend
serum
halflif
enhanc
adcc
activ
may
necessari
avfc
drug
potenti
regard
effici
costeffect
rapid
plantbas
bioproduct
greenhous
facil
facilit
endeavor
may
open
uniqu
possibl
lectibodybas
antivir
drug
develop
rodent
femal
spraguedawley
rat
charl
river
laboratori
wilmington
usa
weigh
approxim
g
singledos
biodistribut
studi
femal
balbc
mice
jackson
laboratori
repeateddos
toxic
studi
hous
temperatureand
humiditycontrol
environ
altern
lightdark
cycl
free
access
standard
diet
water
experiment
procedur
approv
univers
louisvil
institut
anim
care
use
committe
rhesu
macaqu
two
adult
femal
rhesu
macaqu
indian
origin
weigh
kg
respect
select
coloni
new
iberia
research
center
univers
louisiana
lafayett
hous
pharmacokinet
pk
studi
care
conform
guidelin
committe
care
use
laboratori
anim
anim
fed
primatespecif
diet
purina
supplement
daili
fresh
fruit
andor
veget
anim
assess
conduct
anesthesia
experiment
protocol
procedur
review
approv
univers
louisiana
lafayett
anim
care
use
committe
deconstruct
tobamoviru
replicon
system
magnicon
icon
genet
use
express
ah
ah
variant
n
benthamiana
ah
genbank
ah
variant
code
sequenc
n
benthamiana
codon
optim
genbank
avaren
gener
synthet
subclon
magnicon
vector
via
standard
molecular
biolog
subclon
procedur
use
nco
isac
restrict
site
plant
express
ah
ah
variant
perform
use
magnicon
system
provector
ah
ah
variant
use
provector
vector
deliv
n
benthamiana
leav
use
agrobacterium
vacuum
infiltr
method
day
leaf
materi
homogen
precelli
homogen
bertin
technolog
rockvil
md
usa
extract
buffer
pb
ph
mm
ascorb
acid
result
extract
clarifi
centrifug
g
min
analyz
protein
express
sdspage
direct
elisa
ah
avaren
buffer
exchang
lowsalt
buffer
mm
phosphat
buffer
ph
use
molecular
weight
cutoff
mwco
dialysi
cassett
cd
spectra
collect
jasco
cd
spectromet
jasco
great
dunmow
essex
uk
bandwidth
use
pathlength
cuvett
faruv
nearuv
scan
respect
scan
perform
c
correct
blank
lowsalt
buffer
control
protein
concentr
determin
absorb
nm
convert
mean
residu
ellipt
q
molar
ellipt
n
benthamiana
plant
grown
day
within
containedgrowth
room
environ
kentucki
bioprocess
artifici
light
avfc
agrobacterium
vector
transient
deliv
plant
vacuum
infiltr
vacuum
min
postinfiltr
plant
incub
day
whole
leaf
tissu
harvest
mechan
cut
harvest
biomass
mechan
disintegr
buffer
mm
sodium
phosphat
mm
ascorb
acid
ph
totissu
ratio
raw
extract
adjust
ph
use
sodium
hydroxid
celpur
diatomac
earth
de
advanc
miner
ad
gl
filter
aid
extract
de
slurri
clarifi
use
platefram
filter
press
cellulos
pad
ertel
alsop
pack
press
wash
vol
extract
buffer
improv
recoveri
filter
press
filtrat
wash
combin
creat
protein
feed
avfc
clarifi
extract
captur
mabselect
sure
protein
column
ge
healthcar
equilibr
column
volum
cv
mm
sodium
phosphat
ph
clarifi
extract
appli
glass
fiber
filter
resid
time
min
per
cv
feed
applic
column
wash
equilibr
buffer
mm
sodium
phosphat
ph
reach
uv
baselin
column
elut
use
step
arginin
ph
elut
fraction
immedi
neutral
ph
use
tri
ph
buffer
sterilefilt
prior
next
chromatographi
step
avfc
purifi
use
cht
type
ii
column
biorad
column
condit
use
cv
neutral
buffer
mm
sodium
phosphat
ph
equilibr
use
cv
equilibr
buffer
protein
elut
pool
dilut
mscm
water
irrig
wfi
load
onto
column
resid
time
feed
applic
column
wash
cv
equilibr
buffer
reach
uv
baselin
elut
use
linear
gradient
mm
sodium
phosphat
mm
nacl
ph
collect
elut
peak
cht
column
strip
use
mm
sodium
phosphat
nacl
ph
cht
elut
pool
concentr
use
tangenti
flow
ultrafiltr
cassett
sartoriu
follow
diafiltr
dulbecco
pb
invitrogen
retent
steril
filter
use
cellulos
acet
filter
prior
storag
c
avfc
purifi
use
procedur
recombin
b
immun
technolog
new
york
ny
usa
cleav
mannosidas
prozym
hayward
ca
usa
volum
ml
ad
ml
reaction
buffer
suppli
prozym
ml
mannosidas
ml
deioniz
water
control
untreat
reaction
set
manner
replac
mannosidas
deioniz
water
treat
untreat
reaction
incub
h
c
h
elisa
elisa
perform
elisa
plate
coat
treat
untreat
reaction
dilut
ml
mm
carbonatebicarbon
ph
coat
buffer
final
concentr
ng
ml
block
block
buffer
pb
ph
tween
wv
nonfat
dri
milk
serial
dilut
antibodi
avfc
start
mgml
appli
onto
plate
incub
h
c
antibodi
detect
hrpconjug
mous
antihuman
igg
wwwmoleculartherapyorg
fc
southernbiotech
birmingham
al
dilut
tetramethylbenzidin
tmb
substrat
biofx
laboratori
owe
mill
md
usa
use
detect
absorb
nm
measur
plate
reader
biotek
winooski
vt
usa
graph
plot
graphpad
prism
softwar
bind
affin
k
ah
avfc
measur
biacor
instrument
ambient
temperatur
recombin
histag
immun
technolog
immun
technolog
immun
technolog
protein
captur
sensor
chip
nta
follow
manufactur
instruct
surfac
densiti
ru
refer
flow
cell
util
correct
respons
contribut
bulk
shift
occur
equal
sampl
refer
flow
cell
serial
dilut
ah
avfc
made
run
buffer
hpsp
mm
edta
ge
healthcar
inject
flow
rate
mlmin
contact
time
dissoci
time
blank
cycl
run
buffer
perform
sampl
inject
blank
subtract
correct
sensorgram
drift
disturb
affect
refer
subtract
curv
sampl
inject
system
wash
nta
wash
buffer
surfac
regener
nta
regener
solut
replic
nonzero
concentr
ah
avfc
blank
inject
experi
doubl
referenc
thu
verifi
reliabl
immobil
chip
throughout
experi
data
assess
steadyst
bind
analysi
serial
dilut
either
ah
start
mm
avfc
start
mm
coat
plate
duplic
three
pseudovirus
h
c
well
wash
three
time
pb
contain
tween
pbst
block
dmem
contain
fetal
bovin
serum
fb
h
c
well
wash
three
time
water
follow
addit
clade
clade
b
clade
c
pseudovirus
h
c
follow
captur
pseudovirus
well
wash
three
time
dmem
contain
fb
wash
away
unbound
virion
next
dmem
contain
triton
ad
well
lyse
virion
releas
core
antigen
lysat
elisa
sino
biolog
beij
china
perform
transfer
lysat
plate
amount
pseudoviru
captur
ah
avfc
obtain
base
standard
start
pgml
serial
dilut
antivir
activ
avfc
assess
base
reduct
luciferas
report
gene
express
infect
cell
envpseudotyp
virus
assay
perform
triplic
essenti
describ
elsewher
antivir
activ
reflect
ic
sampl
concentr
yield
rel
luminesc
unit
rlu
compar
viru
control
subtract
background
rlu
envpseudotyp
virus
prepar
cotransfect
gnti
cell
american
type
cultur
collect
atcc
variou
envexpress
plasmid
envdefici
backbon
vector
titrat
cell
determin
optim
viral
dilut
yield
rlu
sampl
viru
prepar
incub
h
c
ho
cell
per
well
ad
h
luciferas
activ
measur
use
luciferas
assay
system
promega
fresh
pbmc
zenbio
research
triangl
park
nc
usa
stimul
phytohemagglutinin
pha
roch
indianapoli
usa
mgml
h
c
humid
environ
contain
co
vv
rpmi
gibcoinvitrogen
carlsbad
ca
usa
aimv
medium
supplement
fb
hyclon
mgml
streptomycin
uml
penicillin
lglutamin
acid
hepe
crpmi
pha
blast
grown
crpmi
supplement
uml
recombin
human
zeptometrix
buffalo
ny
usa
sampl
viru
solut
incub
h
c
co
prior
addit
cell
per
well
h
cultur
media
chang
h
incub
upon
addit
lysi
buffer
triton
plate
store
c
ic
express
reduct
determin
accord
manufactur
protocol
sino
biolog
beij
china
assay
perform
quadrupl
viru
strain
bind
affin
k
recombin
human
fc
gamma
receptor
fcgr
ia
iiia
avfc
measur
biacor
instrument
ambient
temperatur
avfc
captur
sensor
chip
via
antihuman
igg
fc
antibodi
isotyp
vari
concentr
recombin
fcgr
use
analyt
briefli
monoclon
mous
antihuman
igg
fc
antibodi
isotyp
mgml
immobil
sensor
chip
ge
healthcar
bioscienc
reson
unit
ru
use
human
antibodi
captur
kit
ge
healthcar
bioscienc
refer
flow
cell
immobil
antibodi
correct
respons
contribut
bulk
shift
occur
equal
sampl
refer
flow
cell
avfc
captur
antihuman
igg
fc
chip
surfac
densiti
ru
fcgri
sensorgram
figur
raw
color
line
fit
black
line
curv
repres
fcgri
concentr
fcgr
bind
avfc
demonstr
bd
facsaria
flow
cytomet
use
fcgri
fcgriiia
tzmbl
cell
nih
aid
reagent
program
initi
background
bind
avaren
tzmbl
cell
block
incub
avfc
mannan
mixtur
block
avfc
fcgrexpress
cell
mix
h
room
temperatur
follow
three
independ
wash
dulbecco
pb
dpb
avfc
bound
fcgr
detect
incub
cell
goat
f
ab
antihuman
igg
fc
fitc
fluorescein
isothiocyan
secondari
antibodi
h
cell
wash
three
time
dpb
cell
fix
paraformaldehyd
analyz
flow
cytomet
nonfcgrbind
avfc
mutant
use
neg
control
human
igg
k
util
posit
control
analysi
perform
triplic
percent
bind
taken
percentag
total
viabl
cell
popul
fluoresc
intens
greater
cellonli
control
primari
isol
nih
aid
reagent
program
viru
propag
infect
phastimul
pbmc
healthi
donor
spinocul
g
room
temperatur
h
viru
passag
twice
phastimul
pbmc
stock
store
c
use
human
pbmc
obtain
ficollhypaqu
gradient
centrifug
allow
adher
polystyren
flask
h
nonadher
cell
collect
stimul
h
mgml
phal
crpmi
lymphocyt
nk
effector
cell
magnet
separ
pbmc
monoclon
antibodi
mab
respect
miltenyi
biotech
auburn
ca
usa
lymphocyt
infect
moi
approxim
h
lymphocyt
initi
propag
day
crpmi
supplement
phal
mgml
uml
follow
mainten
nk
cell
propag
crpmi
supplement
uml
next
infect
lymphocyt
nk
cell
effectortarget
cell
e
ratio
coincub
variou
concentr
avfc
respect
plate
h
supernat
sampl
detect
elisa
zeptometrix
buffalo
ny
usa
control
well
lack
compound
contain
nk
cell
effector
control
lymphocyt
nk
cell
viral
replic
control
well
lack
compound
nk
cell
lymphocyt
includ
everi
plate
assay
perform
triplic
viru
inhibit
calcul
follow
inhibit
ut
concentr
supernat
well
contain
given
compound
ut
concentr
well
lack
compound
cryopreserv
human
pbmc
three
differ
donor
purchas
precis
bioservic
frederick
md
usa
cell
viabil
pbmc
three
differ
donor
assess
flow
cytometri
stain
propidium
iodid
dye
exclud
live
cell
data
acquir
bd
facscalibur
bd
bioscienc
san
jose
ca
usa
count
event
per
sampl
analys
carri
cellquest
pro
softwar
bd
bioscienc
cona
mgml
pb
use
control
freshli
thaw
human
pbmc
three
differ
donor
precis
bioservic
cultur
day
analyz
flow
cytometri
dual
fluoresc
stain
mab
purchas
bd
pharmingen
san
diego
ca
usa
briefli
cell
cultur
transfer
plate
roundbottom
tube
wash
inactiv
fb
pb
wash
solut
block
min
purifi
rat
antimous
mous
bd
fc
block
cell
incub
dark
fitcconjug
mab
combin
peconjug
anti
hladr
mab
min
ice
final
wash
step
data
acquir
bd
facscalibur
bd
bioscienc
san
jose
ca
usa
count
event
per
sampl
analyz
use
bd
cellquest
pro
softwar
bd
bioscienc
cona
mgml
pb
use
control
pbmc
differ
blood
donor
precis
bioservic
cultur
presenc
mgml
avfc
day
concentr
interleukin
il
eotaxin
granulocytemacrophag
colonystimul
factor
gmcsf
granulocyt
colonystimul
factor
gcsf
interferon
gamma
ifng
interferonginduc
monocyt
chemoattract
macrophag
inflammatori
protein
mip
tumor
necrosi
factor
tnf
tnfb
evalu
cultur
supernat
luminex
system
millipor
use
milliplex
human
cytokinechemokin
kit
accord
manufactur
instruct
data
gener
xponent
softwar
individu
elisa
use
evalu
amount
cellcultur
supernat
collect
pbmc
cultur
h
incub
presenc
avfc
mgml
control
mgml
cona
pb
elisa
readysetgo
kit
purchas
ebiosci
use
experi
follow
manufactur
instruct
experi
repeat
total
least
two
time
anim
randomli
divid
three
group
n
receiv
endotoxin
free
sampl
includ
avfc
mgkg
avaren
mgkg
equival
volum
formul
buffer
mm
histidin
ph
mm
sucros
respect
administ
tail
vein
inject
follow
treatment
blood
sampl
collect
tail
vein
variou
time
point
serum
prepar
centrifug
g
min
day
posttreat
rat
sacrif
blood
collect
via
posterior
vena
cava
termin
potassiumedta
anticoagul
whole
blood
collect
complet
blood
count
wwwmoleculartherapyorg
evalu
effect
repeat
avfc
dose
mice
randomli
assign
three
group
n
inject
subcutan
buffer
control
mgkg
avfc
mgkg
avfc
twice
week
week
mous
weight
assess
inject
anim
sacrif
day
blood
collect
inferior
vena
cava
kidney
liver
spleen
heart
lung
excis
weigh
fix
buffer
formalin
h
place
ethanol
use
complet
blood
count
carri
blind
manner
mous
sampl
n
hemavet
system
drew
scientif
standard
mous
blood
follow
paramet
quantifi
potassiumedta
anticoagul
whole
blood
red
blood
cell
count
rbc
cell
per
millilit
total
differenti
leukocyt
count
neutrophil
lymphocyt
monocyt
eosinophil
basophil
quantit
cell
per
millilit
percent
hemoglobin
concentr
hgb
gram
per
decilit
hematocrit
hct
percent
mean
corpuscular
volum
mcv
femtolit
mean
cell
hemoglobin
mch
picogram
mean
cell
hemoglobin
concentr
mchc
gram
per
decilit
red
cell
distribut
width
rdw
percent
platelet
count
plt
cell
per
millilit
mean
platelet
volum
mpv
femtolit
level
follow
serum
chemistri
paramet
assess
differ
analyz
twoway
anova
serum
albumin
alb
alkalin
phosphatas
alkp
amylas
ami
alanin
aminotransferas
alt
blood
urea
nitrogen
bun
calcium
ca
cholesterol
chol
creatinin
creat
globulin
glob
glucos
glu
phosphoru
pho
total
bilirubin
tbil
total
protein
tp
avaren
avfc
concentr
quantit
serum
sampl
elisa
avfc
plate
coat
ml
per
well
mgml
protein
scienc
meriden
ct
usa
overnight
incub
c
plate
block
nonfat
dri
milk
pb
contain
tween
pbst
sampl
dilut
block
buffer
ad
incub
c
h
avfc
detect
mous
antihuman
igg
fc
conjug
horseradish
peroxidas
hrp
southernbiotech
birmingham
al
usa
plate
develop
sureblu
tmb
microwel
peroxidas
substrat
reaction
stop
n
h
final
absorb
nm
nm
measur
biotek
synergi
ht
plate
reader
avaren
detect
carri
sandwich
elisa
use
mous
monoclon
antiavaren
igg
guinea
pig
antiah
serum
produc
laboratori
captur
detect
antibodi
respect
goat
antiguinea
pig
igg
conjug
hrp
santa
cruz
biotechnolog
dalla
tx
usa
use
secondari
antibodi
avaren
quantif
similar
previous
describ
avfc
serial
dilut
purifi
avfc
avaren
run
parallel
gener
respect
standard
curv
siv
neutral
assay
carri
white
opaqu
plate
tzmbl
cell
host
cell
three
strain
siv
propag
cell
experi
briefli
avfc
prepar
serial
dilut
start
mgml
mgml
addit
well
left
serv
control
contain
drug
drug
viru
growth
medium
drug
viru
incub
togeth
c
h
amount
viru
dilut
give
appropri
amount
luciferas
signal
least
background
signal
tzmbl
cell
ad
well
plate
incub
c
day
point
cell
lyse
ml
luciferas
assay
reagent
ad
plate
immedi
read
luminescenceen
plate
reader
rlu
convert
percent
infect
use
valu
nodrug
control
well
infect
valu
plot
drug
concentr
fit
nonlinear
regress
use
graphpad
prism
softwar
cell
previous
isol
rhesu
macaqu
mln
cryopreserv
infect
cultur
rpmi
supplement
fb
uml
human
tonbo
bioscienc
uninfect
cell
also
cultur
control
group
cultur
monitor
express
use
commerci
elisa
kit
sino
biolog
beij
china
infect
confirm
posit
elisa
test
cell
harvest
block
solut
pbst
contain
bsa
human
fc
block
bd
min
ice
cell
wash
success
stain
mgml
avfc
goat
antihuman
iggfitc
secondari
antibodi
abcam
flow
cytometri
perform
bd
facscan
system
captur
cell
popul
gate
live
lymphocyt
unstain
cell
use
determin
background
fluoresc
two
adult
femal
rhesu
macaqu
weigh
kg
respect
administ
bolu
intraven
inject
avfc
equal
dose
mgkg
respect
blood
sampl
h
place
tube
contain
edta
plasma
separ
centrifug
assay
avfc
elisa
use
vari
concentr
purifi
avfc
spike
neat
plasma
ngml
standard
determin
concentr
drug
assay
lower
limit
quantif
ngml
plasma
concentr
avfc
plot
time
pk
paramet
estim
pk
solver
group
mean
sem
deriv
valu
obtain
three
individu
replic
assay
perform
least
twice
independ
unless
otherwis
note
data
outlier
determin
statist
analysi
use
grubb
test
p
exclud
analysi
statist
signific
analyz
oneway
anova
bonferroni
posttest
wilcoxon
matchedpair
sign
rank
test
indic
figur
legend
use
graphpad
prism
softwar
differ
consid
statist
signific
p
data
gener
analyz
present
studi
avail
correspond
author
reason
request
complet
glycan
array
data
figur
avail
http
www
functionalglycomicsorgglycomicssearchjspresultjsp
queri
avaren
catal
code
sequenc
avaren
deposit
genbank
ash
nm
coinventor
patent
relat
find
work
us
patent
number
